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A B S T R A C T
Background
Several clinical studies have compared single with tandem (also called double) autologous stem cell transplantation (ASCT) as first-line
treatment in patients with symptomatic multiple myeloma (MM), one of the leading indications for ASCT worldwide.
Objectives
The present Cochrane Review compares tandem autologous stem cell transplantation (TASCT) with single autologous stem cell
transplantation (SASCT) as first-line treatment in patients with symptomatic MM with respect to overall survival (OS), event-free
survival (EFS), quality of life (QoL) and treatment- or transplantation-related mortality.
Search methods
We systematically identified controlled trials published between January 1995 andMay 2011 in two bibliographic databases (MEDLINE
and CENTRAL) and in clinical trial registries.
Selection criteria
One researcher screened references for controlled trials to determine eligibility for the systematic review (SR) according to pre-specified
inclusion and exclusion criteria, reflecting characteristics of disease and the interventions. We required a minimal set of details to be
reported for observational studies for the studies to be included.
Data collection and analysis
We critically evaluated eligible trials with respect to quality of design and actual performance. One researcher extracted individual trial
results, which were checked by another researcher. We recapitulated the results of the individual trials in a standardised way for the SR
in order to allow a systematic assessment of potential sources of bias.
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Main results
Overall, we identified 14 controlled studies. One registered randomised controlled trial (RCT) is still recruiting patients at the time
of this review and no clinical results have been published. Two registered RCTs have remained unpublished despite their termination.
Publications on one RCT had been retracted. We excluded five observational studies since neither patients nor treatment regimens were
sufficiently characterised to allow an assessment of potential confounding by indication. We conducted a SR of study designs, definition
of endpoints, treatment regimens and baseline characteristics of patients in the five included RCTs (two full-text publications, three
conference presentations) enrolling1506 patients in total. Because we identified substantial clinical and methodological heterogeneity,
we refrained from conducting a formal meta-analysis.
While we included only previously untreated, symptomatic patients with MM the treatment regimens differed notably with respect to
acute toxicity, between trials and also between study arms. Compared to state of the art treatment standards, the treatment regimens
applied in all trials have to be considered as below standard from a contemporary perspective in at least one component.
Three trials were likely to have the potential of being highly biased while two RCTs had a moderate potential for bias. The observed
treatment effects in the set of included trials may have been influenced by a steep decrease in compliance with the second ASCT and
the concomitant selection of patients. In addition, OS data were confounded by the treatment subsequent to first-line therapy.
OS was statistically significantly improved in one trial only. While EFS was prolonged in four of the five trials, the median prolongation
ranged between three to 12 months, with an uncertain direction of bias in the individual trials. QoL was not reported in any study.
Results concerning treatment- or transplantation-related mortality could not be adequately assessed due to substantial differences in
definitions between trials and low reporting quality.
Authors’ conclusions
We did not consider any study to be sufficiently informative for contemporary treatment decisions concerning the question single versus
tandem ASCT in view of inherent biases. In addition, none of the trials integrated the so-called “novel agents” which are now considered
standard treatment for MM. To improve the quality of future studies, sample size calculations should consider the potentially steep
decrease in compliance with the second ASCT. Reporting of results of treatment- or transplantation-related mortality should clearly
specify the type and number of events (the numerator) in a well-defined population (the denominator).
P L A I N L A N G U A G E S U M M A R Y
High-dose chemotherapy plus single vs tandem autologous transplantation as initial treatment for multiple myeloma
Multiple myeloma is a cancer of antibody-producing cells in the bone marrow. It causes bone destruction and patients are usually at a
higher risk for infections and renal damage. Autologous stem cell transplantation has been established as standard initial treatment for
fit patients with symptomatic multiple myeloma. During autologous stem cell transplantation, blood-forming stem cells are removed
from the patient prior to intense chemotherapy and later given back to the same patient. The chemotherapy is aimed at killing
tumour cells (the higher the dose the more tumour cells are killed) but also affects normal blood-forming cells that are needed to fight
infections, transport oxygen and control bleeding. By giving the patient back his or her own blood-forming cells, the recovery from
the chemotherapy is notably faster and better. Since it is unclear whether autologous stem cell transplantation as initial treatment of
multiple myeloma should be performed once or twice, we systematically searched for publications addressing the question whether
the acute toxicity of autologous stem cell transplantation is counterbalanced by a long-term benefit for the patient. Several studies in
which patients undergoing one treatment with autologous stem cell transplantation were compared to patients undergoing autologous
stem cell transplantation twice were identified. Only five of 14 studies identified could be analysed in the present systematic review. We
were interested in long-term benefit for patients with respect to overall survival or so called event-free survival, that is survival without
disease progression. Quality of life and treatment-related mortality should also be analysed in clinical studies.
When the included studies were analysed with respect to treatment regimen and design characteristics, all turned out to have method-
ological problems which do not allow us to draw firm conclusion from the findings. Since the way to treat multiple myeloma has
changed since the performance of the included trials, conclusions cannot be drawn with respect to contemporary treatment decisions.
We also noted that reporting of completed trials needs to be improved.
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B A C K G R O U N D
Description of the condition
Multiple myeloma (MM) is a haematological malignancy that
contributes to approximately 15%of haematological malignancies
and close to 27% of all haematopoietic cell cancer-related deaths
(Munshi 2008). The incidence increases steadilywith age and 75%
of patients are older than 60 years (Durie 2001; Alexander 2007).
Myeloma cells derive from antibody-producing B-cells, therefore
MMis characterised by the presence of often non-functionalmon-
oclonal immunoglobulins in the serum or urine, or both (Laubach
2011). Patients frequently present with bone pain or increased
susceptibility to infections, or both. Among other factors, the re-
lease of calcium from bone into the blood stream leads to hyper-
calcaemia; and the generally high protein concentration in serum
may result in renal failure. End-organ damage is the decisive factor
that indicates the necessity of starting aggressive treatment and it
has a major impact on the quality of life (Anderson 2008).
Over decades, MM has been classified according to the Durie-
Salmon (DS) staging system which aims at correlating clinical
features with an estimate of myeloma cell mass (Durie 1975).
Recently, a new international staging system (ISS) based solely
on two readily available laboratory tests (β2-microglobulin and
albumin) has been developed (Greipp 2005).
Despite progress in the understanding ofMM, especially regarding
pathophysiology, its main causes remain unknown (Durie 2001;
Alexander 2007). There seems to be more than one genetic path-
way to MM and in addition to translocations, karyotypic insta-
bilities are often observed. Hyperdiploid or non-hyperdiploid tu-
mours carry different numbers of chromosomes and the two classes
differ with respect to chromosomal content, stromal dependency
and aggressiveness of the tumours (Fonseca 2009).
The clinical course of MM is very heterogeneous with overall sur-
vival (OS) ranging frommonths to decades depending on the stage
of disease or the presence of prognostic factors for example (Gertz
2007). Of unfavourable prognosis are an especially bad perfor-
mance status, older age, high plasma cell labelling index, and high
β2-microglobulin or lactate dehydrogenase levels (Fonseca 2007).
More recently, cytogenetic changes such as chromosome 13 and
chromosome 11 abnormalities are also proposed to have a strong
correlationwith aworse outcome (Fonseca 2009;Nahi 2011). The
high frequency of patients who either are or become refractory to
treatment, a feature also markedly impacting on treatment out-
come, is thought to be related to the strong interactions between
tumour cells and the surrounding stroma (Podar 2009).
Patients with stage I, II, and III disease according to the ISS have a
median OS of 62, 44 and 29 months, respectively (Greipp 2005).
An improvement of OS was demonstrated in the last decade, both
in the relapsed setting as well as from diagnosis, with a doubling
in OS for patients who were treated with one or more of the novel
agents (thalidomide, lenalidomide or bortezomib) (Kumar 2008;
Johnsen 2010; Turesson 2010).
Therapeutic strategies in MM not only focus on prolonging OS
but also to induce tumour response, inhibit tumour progression
and delay disease-related complications (Anderson 2008, Durie
2010). The surrogacy of tumour response with survival is still
under discussion, however (Durie 2008; Harousseau 2009; Durie
2010). Validation of response as a patient-relevant outcome is
mainly hampered by the dynamic changes in treatment from the
high-dose combination chemotherapy approaches of the 1990s to
integration of novel agents (Durie 2010).
One treatment approach for symptomatic MM was to intensify
chemotherapy, either by increasing doses or by using combina-
tions of multiple drugs (reviewed in Hahn 2003). The first high-
dose chemotherapy schemes resulted in high toxicity and exten-
sivemyelosuppressionwithout substantial prolongationof survival
(Barlogie 1986; Myeloma Trialists 98). Outcomes after intensive
treatment were improved only by autologous stem cell transplan-
tation (ASCT).
Description of the intervention
Eligibility for transplantation remains one of the main determi-
nants of the treatment strategy until today (for example Kortüm
2010; NCCN 2011). A number of randomised trials have been
performed comparing high-dose chemotherapy supported by
ASCT with conventional chemotherapy as first-line treatment
(cited in Levy 2005; Koreth 2007). The subsequent meta-analy-
ses did not provide evidence for an extended OS after ASCT, but
progression-free survival (PFS) was significantly improved ( Levy
2005; Koreth 2007). Importantly, the size and treatment effects
with respect to both OS and PFS of single autologous stem cell
transplantation (SASCT) over combination chemotherapy were
quite variable in the individual trials (indeterminate, favourable
and even unfavourable in one trial). Accordingly, the meta-ana-
lytical result indicated statistically significant heterogeneity (Levy
2005; Koreth 2007). Although transplantation-related mortality
could be reduced to less than 5% in the majority of ASCT tri-
als, it remained consistently higher after a transplantation regimen
compared to chemotherapy alone, both in RCTs as well as in daily
practice (Jantunen 2006a; Gertz 2008; Jones 2008).
How the intervention might work
Assuming a favourable outcome of SASCT compared to chemo-
therapy, in the early 1990s some investigators concentrated on tan-
dem autologous stem cell transplantation (TASCT) (Harousseau
1992; Barlogie 1997). TASCT corresponds to a second prospec-
tively planned ASCT within a few months after the first ASCT.
TASCT was introduced to further improve or consolidate dis-
ease control as achieved after SASCT in view of a documented
dose-response relationship of melphalan with improved outcome
(Awedan 2002; Giralt 2010).
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Why it is important to do this review
MM is among the leading indications for ASCT in Europe and the
USA (Copelan 2006; Gratwohl 2007). Two randomised studies
comparing TASCT with SASCT as initial treatment in patients
with symptomatic MM have been published as full text publica-
tions (IFM94; Bologna96). Further results from RCTs were pre-
sented at conferences (DSMM-I; GMMG-HD2; MAG95). As
with RCTs comparing SASCT with combination chemotherapy
(see Levy 2005; Koreth 2007), a statistically significant improve-
ment of either survival endpoint was not consistently replicated
in the other trials addressing the same question. This is a classical
starting point for a meta-analysis aiming at determining clinical
or methodical reasons for the observed heterogeneity, either with
respect to statistical significance or with respect to the size of the
treatment effect (Egger 2001; Higgins 2011; Pignon 2001).
Although TASCT has been used as first-line treatment of MM
for more than 16 years now, there is continued controversy about
its value. There is concern that the increased short-term risks as-
sociated with double intensified treatment might call into ques-
tion the benefit of long-term disease control, in all or specific
subgroups of patients (Fermand 2007; Barlogie 2007; Tricot
2008). Thus, an ’acceptable level of toxicity’ for the primary
MM treatment is still unclear. Usually, higher toxicity is ac-
cepted for a curative treatment compared to a palliative treatment
(EMA/CHMP/EWP/520088/2008).
On the one hand, TASCT is an integral component of a “To-
tal Therapy” programme (TT), which currently includes novel
agents in both the induction and maintenance treatment regimen
(Barlogie 1997; Total therapy). Barlogie and colleagues support
TT as a key to the cure of MM (Barlogie 2009). Some investiga-
tors, however, have started to regard MM as a chronic disease and
principally question the value of an intensive (and thereby toxic)
treatment approach (Rajkumar 2008; Attal 2009; Gertz 2009).
O B J E C T I V E S
We systematically reviewed the evidence on the effects of TASCT
compared to SASCT as first-line treatment in MM on overall sur-
vival (OS), event-free survival (EFS) and treatment- or transplan-
tation-related mortality. By systematically reviewing both prospec-
tively planned features of the included trials and actual experiences
recorded during their performance, we aimed to contribute to a
discussion on clinical and methodological issues critical for the
interpretation of the available evidence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Both randomised and non-randomised trials comparing first-line
TASCT with SASCT in patients with symptomatic MM were in-
cluded into the systematic review according to pre-specified inclu-
sion and exclusion criteria (Table 1). All of the inclusion criteria
had to be fulfilled and none of the exclusion criteria for including
a study. Duration of follow-up was not a criterion for selecting
trials.
The reason for including comparative observational studies in the
search for the systematic review was to prepare for customary re-
proaches against RCTs, that is their alleged artificiality or distance
from clinical practice. In order for observational studies to be in-
cluded, however, they had to report on a contemporary control
group and both groups needed to be described with sufficient de-
tail to allow assessment of potential ’confounding by indication’
(Kunz 1998; Klungel 2004; Klein-Geltink 2007; Vandenbroucke
2008). At least baseline characteristics, the treatment regimen and
outcome data for the two groups had to be reported separately for
both groups.
In view of a potentially critical publication bias if only full-text
articles were accepted, conference presentations of RCTs were eli-
gible (Krzyzanowska 2003; Curt 2008; Ramsey 2008; Tam 2008)
while full-text publications only were acceptable for observational
studies.
Types of participants
We included patients with MM at first diagnosis. Prior treatment
was accepted if patients had been treated conventionally (melpha-
lan, prednisone) for a limited time span (up to six months) (see
Differences between protocol and review). No age restriction was
applied.
We excluded patients with a localised form of myeloma as it has
different biological behaviour and requires different treatment.
We also excluded studies in patients with preliminary stages of
MMand the closely relatedmonoclonal gammopathy of unknown
significance as well as smoldering myeloma, for which treatment
is not recommended.
Types of interventions
We included all studies comparing first-line TASCT with SASCT.
We included all trials assessing TASCT regardless of the timing of
transplantation as long as the second transplantation was prospec-
tively planned as first-line treatment, before disease progression.
We accepted all types of induction, conditioning and maintenance
regimens and included studies irrespective of the source of stem
cells.
Types of outcome measures
Ideally, both prolongation of the objective endpoint OS and im-
proved quality of life should be used for demonstrating patient
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benefit (Anderson 2008; Durie 2010). Quality of life measures
were, however, only to be included if they were assessed by vali-
dated instruments. Considerable confounding of OSwas expected
in all included RCTs as all were performed in the years during
which the so-called ’novel agents’, with considerable efficacy in
MM (thalidomide, lenalidomide or bortezomib), were developed
forMM(Kumar 2008). Therefore, EFS can be considered as an in-
dicator of efficacy as long as a deleterious effect on OS could be ex-
cluded, in an analogy to drug development (CPMP/EWP/205/95
2005). It is important to note that EFS also includes laboratory
parameters which signal progression but need not immediately af-
fect the patients’ health status. Since the criteria for progression
became more sophisticated over the time period during which the
included trials were performed, for example by increasing sensi-
tivity with respect to progression using immunofixation, there is
some heterogeneity of definitions used in all included trials (Attal
1996,; Bladé 1998; Durie 2006). The outcome in clinical trials in
oncology is often also assessed by measuring response to therapy.
In view of the different definitions for response in the relevant time
period of TASCT studies, and the ongoing discussion on whether
a (best) response analysis allows a demonstratration of (durable)
benefit for all patients, response was not assessed for the present re-
view (Harousseau 2009a; Moreau 2011) (see Differences between
protocol and review). Treatment- or transplant-related mortality,
sometimes indiscriminately abbreviated as TRM in the original
reports, was to be analysed as a measure of safety (see Differences
between protocol and review).
Search methods for identification of studies
Evidence on the efficacy and safety ofTASCTcompared to SASCT
in the first-line treatment of MM was identified by systematic
electronic searching for literature in two bibliographic databases
(Cochrane Central Register of Controlled Trials (CENTRAL);
MEDLINE) according to the recommendation by The Cochrane
Collaboration (Dickersin 1994;Higgins 2011).We had to exclude
the database EMBASE due to budgetary restrictions and con-
sidered only publications in English, French and German. Since
CENTRAL is updated with randomised controlled trials from
EMBASE through retrospective searches conducted by the UK
Cochrane Centre, up to 2008, EMBASE was at least partially cov-
ered through CENTRAL in our review.
Since observational studies, for example registry reports, were to
be included in addition to RCTs, the search filter was adapted
accordingly (see Appendix 1 and Appendix 2). Overall, the sensi-
tivity of the presented search was lower for observational studies
compared to RCTs due to the choice of bibliographic databases
(CENTRAL is enriched for RCTs only).
The systematic search was restricted in the years of publication
with the starting point of 1995 in order to approximate the estab-
lishment of TASCTas first-line treatment ofMM(Barlogie 1997).
A pilot search was performed in 2007. The systematic search of
the two bibliographic databases MEDLINE and CENTRAL was
performed on 30th of April 2010. The search was updated on the
23rd of May 2011.
Electronic searches
Bibliographic databases (1995 to 2011)
See Appendix 1 for MEDLINE, and Appendix 2 for CENTRAL
search strategy.
Searching other resources
Databases of ongoing trials
Further potential sources for identifying trials were asking clini-
cal experts (personal communications by Alexander Greb, Roland
Schnell) or by browsing reference lists and the following websites
using keywords such as “myeloma AND transplantation”.
www.myeloma.org.
www.onkodin.de.
www.clinicaltrials.gov.
www.controlled-trials.com.
In addition, the Deutsches Krebsstudienregister (German Cancer
Trials Registry) and Google were searched using the names of the
first or senior authors’ of the included trials.
Handsearches
No additional handsearches were performed.
Contact
Authors of the all RCTs were contacted at least once by email or
telephone, or both, for further information.
Data collection and analysis
Information from included studies is either presented by study
in the Characteristics of included studies or by topic: baseline
characteristics, treatment regimen, definition of endpoints, in
Table 2 Table 3; Table 4; and Table 5, respectively. Quality of
reporting and extent of uncertainty due to missing information
was captured for all included studies (Table 6).
Selection of studies
Studies were selected in two steps by one researcher (Figure 1). An
independent meta-analysis published in 2009 and a health tech-
nology assessment (HTA) report published in 2011 were regarded
as control for the comprehensiveness of the search (Kumar 2009;
IQWIG N05-03C). Evidently irrelevant studies (such as animal
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experiments, other treatment approaches for MM or narrative re-
views) were excluded by screening the title and abstract of the ref-
erence identified. The decision was based on the full-text publica-
tion in the case of uncertainty. Selected studies were assessed with
an eligibility form as to whether they meet all inclusion criteria
and none of the exclusion criteria (Table 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Data extraction tables were developed in order to provide a clear
framework for the verifiable collection of data items. Data items
included both elements from prospective planning of the study
(for example the hypothesis for sample size calculation) as well as
the actual experience of the trial (for example compliance with
intended treatment). The following information was collected by
one researcher (FN) and the correctness of the extracted data was
checked for accuracy by another researcher (RS).
Information on study basics such as the setting of the trial (time
period, location), design, basis for sample size calculation, an in-
tention-to-treat analysis (ITT) and number of patients dropping
out, notable inclusion or exclusion criteria, type of reported out-
comes relevant for the present review, and type of publication are
described in the Characteristics of included studies. The most im-
portant aspects for interpretation of the individual study (as dis-
cussed also in the bias section) are also repeated as ’Notes’.
Information from the included trials regarding the following char-
acteristics were grouped per topic (rather than by individual trial)
in order to facilitate the comparison of one feature across all in-
cluded trials.
• Baseline characteristics of patients (n, age, β2-
microglobulin, sex, stage, status at randomisation, type and
number of prognostic factors reported) were extracted for all
included studies (Table 2).
• Intervention details (type of stem cell mobilisation and
source of stem cells, induction, conditioning, maintenance and
salvage treatment) were noted with the aim of highlighting
clinically relevant differences in the treatment regimen between
study arms and between studies, and their deviance from current
treatment standards. The compliance with the intended
treatment schedule and the extent of cross-over (if reported) were
also extracted (Table 3).
• Definitions of outcome measures (OS; EFS: starting point
of the analysis for time-to-event data, definition of relevant
events including the extent of follow up (Table 4); so-called
TRM: definition of numerator (cause of death) and denominator
(type of population), period of observation and additional causes
of death reported in the study) were summarised for all included
studies (Table 5). See also Differences between protocol and
review.
• Results concerning both benefit (OS, EFS) and harm (so-
called TRM or early mortality) of the individual trials were
extracted.
Assessment of risk of bias in included studies
The quality of included trials was critically evaluated according to
methodological criteria listed in Table 6. Several of these criteria
were shown empirically to have an impact on the validity of trial
results and are listed, for example in the CONSORT statement,
theCochraneHandbook for Systematic Reviews of Interventionsusing
RCTs or in the STROBE statement for observational studies (Juni
2001; Moher 2001; von Elm 2008; Higgins 2011). In addition,
characteristics regarded as essential for the interpretation of trials
studying TASCT were discussed, for example acute toxicity of
the treatment regimen or compliance with the treatment plan. A
colour code was applied for the risk of bias table (Figure 2) in
order to indicate compliance with (green) or missing (red) high
quality standards (Table 6), while lack of information was coded
with yellow. The quality of all studies which were deemed eligible
for the review were systematically assessed by one researcher (FN)
and discussed with the senior author (RS).
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Figure 2. Overview of Risk of bias in the set of included trials: Green colour indicates sufficient information
available to verify adequate methods or similar features in both study arms. Red colour is used to highlight
characteristics which were systematically different between study arms and therefore may result in a biased
comparison (both conservative or anti-conservative). Yellow colour indicates lack of (sufficiently detailed)
information.
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Measures of treatment effect
No meta-analysis has been performed for the comparison of
TASCT with SASCT (see Differences between protocol and
review). Results from individual studies are presented in ta-
bles aimed at standardising highly variable reporting (Table 7).
In addition, results are summarised as a narrative (Effects of
interventions).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Overall, 1697 potentially relevant articles, abstracts or conference
presentations were identified by systematic searching for both ran-
domised and non-randomised controlled studies in CENTRAL
and MEDLINE. The comprehensiveness of our search was con-
firmed since all studies that were included either in the recently
published meta-analysis or the HTA report on TASCT (Kumar
2009; IQWIG N05-03C) were also identified by our search. A
flow chart of the systematic search for eligible studies is presented
in Figure 1 according to the recommendations of the PRISMA
statement (Moher 2009).
Twenty-two references dealt with our research question and were
eligible for the systematic review according to pre-specified inclu-
sion and exclusion criteria (Table 1), representing eight RCTs in
total. One additional RCT had been retracted from publication
and was therefore not included (Abdelkefi 2008; Abdelkefi 2009).
Five RCTs were eligible for inclusion in ameta-analysis while three
were ineligible, for various reasons. One RCT was identified as on-
going (currently recruiting patients) so that no data were yet avail-
able NCT01109004. Two trials (DM00-196 and N0265041749)
were reported as completed or terminated in clinical trial registries
but no publicationswith clinical outcome data were available.One
abstract onDM00-196 focused on the reasons forwithdrawal from
the treatment protocol (Wilson 2003). N0265041749 had been
registered as completed in the UK national registry but remained
unpublished. The principal investigator of N0265041749, when
contacted for further information, explained that the study had
been closed due to insufficient recruitment. No further informa-
tion was obtained after having contacted the authors of the other
RCTs.
All of the five otherwise eligible comparative observational studies
(Lahuerta 2003; EBMTR; Kim 2009; Koren 2010; NMSG) were
excluded from the systematic review since they did not sufficiently
describe the included patient population and applied treatment
regimen (see Excluded studies).
Included studies
Description of individual trials
In the following sections, the characteristics of the included studies
with outcomes relevant to the systematic review are briefly sum-
marised individually (Characteristics of included studies). Further
information on the trial design and performance is summarised
below (comparison of characteristics of studies) and listed in detail
(Table 2, Table 3, Table 4, Table 5). The results of individual stud-
ies are described in the section Effects of interventions and Table
7, both sections aiming at standardising highly variable reporting.
• IFM94: Attal and colleagues selected 399 patients younger
than 60 years with symptomatic disease predominantly of Durie-
Salmon (DS) stage II and III. Patients were randomised before
induction treatment by a 2 x 2 factorial design to: a) TASCT or
SASCT and b) bone marrow or peripheral blood stem cells.
Treatment groups were reported to have similar baseline
characteristics (Table 2). Transplantation regimens differed
between the first and second ASCT in the TASCT arm (Table 3).
• MAG95: patients with MM (stage II and III) younger than
56 years were selected for MAG95 (Table 2); 227 patients were
randomised before induction treatment by a 2 x 2 factorial
design between: a) TASCT or SASCT and b) selection of
CD34+ positive cells from peripheral blood stem cell grafts, or
no selection (Table 3). Treatment groups were reported to have
similar baseline characteristics (Table 2). Transplantation
regimens differed between arms and between the first and second
transplantation in the TASCT group (Table 3).
• The Bologna96 trial also assessed the concept of TASCT
compared to SASCT in 321 patients younger than 60 years with
symptomatic MM stage I, II and III. Patients were randomised
before induction treatment to either one or two ASCT with
similarly dosed preparative regimens (Table 3). Treatment groups
were reported to have similar baseline characteristics (Table 2).
• The GMMG-HD2 included between 358 and 485 patients
with DS stage II and III MM younger than 66 years (numbers
inconsistent between different conference presentations). While
only patients with at least stable disease were randomised
between one or two ASCT with identical preparative regimens
(Table 3), an optional randomisation between two induction
regimens was reported for this trial. It remained unclear whether
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the randomisations were performed and analysed under the same
protocol. Treatment groups were reported to have similar
baseline characteristics (Table 2).
• DSMM-I evaluated a novel conditioning regimen including
bone marrow irradiation preceding SASCT and compared it to
the ’standard’ TASCT regimen as control (Table 3). Overall, 198
patients younger than 60 years with SD stage II and III disease
were randomised if they had at least stable disease after induction
and had successfully mobilised a sufficient number of stem cells.
Treatment groups were reported to have similar baseline
characteristics (Table 2).
Comparison of characteristics of studies
In the following section, general observations on the set of in-
cluded trials are discussed with reference to more detailed tables
on baseline characteristics (Table 2), treatment regimen (Table 3),
and definition of endpoints (Table 4; Table 5).
Baseline characteristics of included patients
Information on allocation was limited for the majority of studies.
All authors documented the similarity of study groups however,
either by referring to P values or by presenting similar values for
selected prognostic factors. The only prognostic factors described
for all studies were age, β2-microglobulin and stage (Table 2). For
MAG95, baseline characteristics of treatment arms were not re-
ported separately. While MAG95 included the youngest patient
population of the set of included trials, the Bologna96 trial in-
cluded the highest proportion of patients with symptomatic stage
I disease. In DSMM-I and GMMG-HD2, only patients respond-
ing to induction treatment were included. No obvious hierarchy
concerning baseline risk between studies could be determined in
view of the heterogeneity of eligible age range, stage or prognostic
factors.
Treatment plan and compliance
None of the included trials assessed exactly the same treatment
strategy. All trials deviated from what would be considered stan-
dard today in at least one component of the ASCT regimen
(SASCT or TASCT). Different combinations or sequences of in-
duction, mobilisation, conditioning ormaintenance regimenwere
used. Rather than repeating one ASCT regimen, the TASCT reg-
imens used in IFM94 and MAG95 could be described as dose-
escalating since the intensity of the preparative regimen used for
the initial ASCT was lower than for the second ASCT. Compli-
ance was usually high with the first or only transplantation in all
trials but was highly variable for the second transplantation (Table
3). Causes of non-compliance were either myeloma-, toxicity- or
procedural-related, or were based on patients’ preferences: patients
developed contra-indications for second transplantation while on
the trial, or an insufficient number of stem cells precluded further
ASCT. A notable number of patients refused further treatment or
were denied coverage. Among the reported reasons for non-com-
pliance, refusal by patients was the most common reason for not
performing the second transplantation. The lowest compliance
with second transplantation was observed in Bologna96 (65%)
and GMMG-HD2 (52% of evaluable patients).
Information on maintenance or salvage treatment (treatment after
relapse) was limited for the majority of trials. First, it was often
not reported separately for the two arms (DSMM-I; GMMG-
HD2; MAG95) and second, only proportions of types of salvage
treatment were reported but not the outcome. Patients crossing-
over to the other treatment arm were only reported for DSMM-I,
where 18%of patients from the SASCTcrossed over to theTASCT
arm without information on their status at the time of cross-over.
Assessment of treatment effect
Although heterogeneity of disease and potential differences in re-
sponse criteria existed (locally or over time), no trial reported on
efforts of standardisation across the usually high number of study
centres (see Characteristics of included studies).
Excluded studies
Randomised trials
Sonneveld 2007 was excluded from the systematic review due to
the non-myeloablative approach of intermediate dosing of mel-
phalan in the control arm (two times 70 mg/m²melphalan instead
of one high dose of melphalan 140 mg/m²).
Observational studies
Comparative observational studies were to be included in the tri-
als if both the population and treatment regimen were described
in sufficient detail. None of the observational studies identified
allowed us to adequately assess or rule out ’confounding by indica-
tion’, the most critical issue for interpretation of treatment effects
from observational studies (Kunz 1998; Vandenbroucke 2008).
Therefore those data, mostly registry data (EBMTR; Kim 2009;
NMSG) or single centre experience (Lahuerta 2003; Koren 2010),
were not formally included in this systematic review.
Total therapy (no RCT)
TASCT is an integral part of ’Total therapy’ (TT), developed by
Barlogie and colleagues (Total therapy). TT publications were not
included in the systematic review for the following reason: TT
was supported by an historical comparison of a single-armed study
in a single specialised centre, both initially (TT1; Barlogie 1997)
and upon development of further TTgenerations (Barlogie 2009).
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With this design, selection bias at enrolment and potentially infor-
mative censoring during study conduct can neither be assessed nor
excluded. Of note, all generations of the total therapy program,
except TT1, integrate the so-called novel-agents either before or
after TASCT, or both, which is regarded as a critically different
treatment approach compared to that in the set of included RCTs
(Barlogie 2006).
Risk of bias in included studies
Assessment of the potential of bias was based on several methodical
aspects and actual experience during (for example compliance) or
after the performance of the trial (for example publication type)
(Table 6; Figure 2).
Most information was available for classification of risk of bias for
IFM94 and Bologna96, which were published as full-text publica-
tions, compared to the trials available as conference presentation
only (DSMM-I; GMMG-HD2; MAG95). The quality of the tri-
als was rated both according to prospective elements such as the
availability of an ITT analysis, the reported basis for sample size
calculation or whether a detailed description of the baseline would
allow the reader to rule out clinically relevant if not statistically
relevant differences in baseline characteristicss (see Figure 2).
Bias was also assessed based on the time point of analysis, that
is the extent of follow-up or data maturity. There is consensus
that minimal median follow-up in MM should be more than four
years (Harousseau 2009a; Tricot 2009). RCTs with follow-up of
more than four years were marked in green, while trials with less
or insufficient information were coded in red or yellow (see Figure
2). Since neither conference presentations nor abstracts contained
sufficient data to ascertain the validity of the results, the lack of
a full-text publication was also rated as a negative feature (Tam
2008).
The overall potential for bias (direction of bias unclear) was rated
per study (Figure 2) based on the most important factors involved
(Table 6). With respect to individual endpoints, OS was con-
sidered to be more biased compared to EFS and so-called TRM
since, in addition to transplantation regimen and compliance (see
Other potential sources of bias), follow-on treatment could have
impacted on the effect on OS.
IFM94, MAG95 and DSMM-I were considered as having the
potential to be highly biased, with an unclear direction of bias
(conservative or anti-conservative). Most relevant issues for the
classification of IFM94 were the dose-escalating TASCT regimen
(Other potential sources of bias), low compliance with the second
ASCT and unclear type and effect of follow-on treatment (Table
3). The critically limited amount of information due to its publica-
tion type (Selective reporting), together with TASCT and SASCT
regimens which would be regarded as non-standard today (Other
potential sources of bias), were decisive for classifying MAG95 as
potentially highly biased. In view of its relatively short follow-up,
apparently unstable results with multiple crossings at the right end
of the Kaplan-Meier curves and high cross-over rate, DSMM-I
was also rated as having the potential to be highly biased, with an
unclear direction of bias.
Since Bologna96 and GMMG-HD2 (at least) evaluated a stan-
dard-dose TASCT conditioning regimen from a contemporary
perspective, they were (rather subjectively) rated as moderately
biased despite the steep decrease in compliance with the second
ASCT (see also Discussion).
Allocation
Information on allocation was limited for the majority of studies
(see Characteristics of included studies). While all reports were
reported as randomised, only the full-text articles of IFM94 and
Bologna96 allowed the assessment of procedural aspects of ran-
domisation which are necessary to judge whether, for example,
concealment of allocation would be achieved, or not.
Blinding
In view of the obvious differences in treatment plan, none of the
studies were blinded. This is acceptable for ethical reasons but
heightens the importance of objective outcome assessment.
Incomplete outcome data
The steep decrease in compliance with the second ASCT most
likely results in a null bias, that is a conservative shift of the treat-
ment effect in an ITT analysis. The overall shift of the treat-
ment effect was, however, unclear in view of the dilution of ef-
fects by non-compliance, unpredictable selectionbias of compliant
patients and further confounding by salvage treatments (Schulz
2002; Wheatley 2006).
ASCT as first-line treatment of MM was followed by further lines
of therapy as salvage treatment in case of relapse or progression
(see Table 3). Since all included RCTs coincided with the clinical
development of several so-called ’novel agents’ with considerable
activity in myeloma, the type and outcome of follow-on treatment
is critically important for the interpretation of OS. Information
on the type of salvage treatment per arm, if at all available, was
insufficient for all trials. No or limited information was available
concerning completeness of follow-up or cross-over (before an
event) for most RCTs.
Selective reporting
Both the reported items and printing quality differed widely be-
tween full-text publications, abstracts and conference presenta-
tions. Endpoints were only superficially defined in most trials,
with only Bologna96 referring to censoring rules in time-to-event
analyses(Table 4). Kaplan-Meier (KM) curves were not available
for OS in the full-text publication of Bologna96 and not for EFS
in the conference presentation of MAG95.
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Both definitions of the relevant period of observation and causes
of death to be listed as so-called TRM remained unclear in the
majority of trials (indicated by depicting the latter as ’so-called
TRM’) (Table 5). Only interim data on ’toxic death’ were available
forMAG95 (seeDiscussion). In addition,mainly proportions (and
not number of deaths in a specified population) were reported in
the majority of trials, leaving room for interpretation concerning
the denominator used for the calculation of the proportions, which
is especially important in view of usually lower compliance with
the second transplantation (Table 3).
Only those studies in which statistically significant improvements
in survival outcomes were observed were published as full-text
publications (IFM94; Bologna96) while the non-significant re-
sults of three further RCTs were available on the Internet as con-
ference presentations only (MAG95, GMMG-HD2, DSMM-I).
Two RCTs remain unpublished in spite of being registered as ter-
minated (DM00-196; N0265041749). According to the princi-
pal investigator, DM00-196 was closed due to insufficient recruit-
ment. The dependency of publication on the size of the treatment
effect (and the associated statistical significance) is an obvious sign
of publication bias which could only be detected by a meticulous
literature research or interaction with experts who had been aware
of the trials during their performance.
Selective reporting of outcomes, apart from uncertainty due to un-
clear definitions (see Incomplete outcome data; Table 4; Table 5),
was not observed for the endpoints considered for this systematic
review.
Other potential sources of bias
Impact of treatment plan and compliance
While the cumulative dose was higher in the TASCT arm for all
studies, dose density differednotably betweenTASCTandSASCT
in IFM94, MAG95 and DSMM-I. When assessing the compa-
rability of treatment toxicity between the SASCT and TASCT
regimens within studies, some SASCT regimens were consider-
ably more toxic, either overall (DSMM-I) or at an earlier time
point (with higher dose density), compared to a sort of dose-
escalating scheme in the TASCT arm with ’softer’ conditioning
for the first ASCT (Table 3 ). Total body irradiation (TBI) was
omitted for conditioning before the first ASCT in the TASCT
arm of IFM94, while the second ASCT was identical to the only
ASCT in the SASCT arm. The first ASCT for the TASCT arm in
MAG95 involved an overall lower dose of chemotherapy without
TBI and CD34-selection in contrast to the only transplantation
in the SASCT arm. Twice as many patients died early in the group
receiving CD34-selected grafts in MAG95 (N = 14 versus n = 7).
In view of the treatment plan for MAG95, with differences in the
timing and intensity of treatment regimens (Table 3), a clinically
relevant interaction between CD34-selection and randomisation
to the TASCT or SASCT arm was likely.
On the one hand, delayed onset of intense chemo(radio)therapy
may initially favour the TASCT arm in the trials with respect to
sparing patients’ acute toxicity (potential lead time bias). On the
other hand, insufficient dose intensity up to and including the first
ASCT may leave patients who discontinue prior to second trans-
plantation undertreated. This is especially important for IFM94,
in which the compliance with the second transplantation was only
78%. The possibility of these biases was coded with a red colour
(Figure 2; see also Incomplete outcome data (attrition bias).
Cross-over from the SASCT to the TASCT arm was only reported
for the DSMM-I trial (18% cross-over) while no information was
available about the time point of crossing-over (before or after
progression). Cross-over also confounds the reported results by
potential null and selection bias.
Effects of interventions
Initially, we planned toperformameta-analysis of the five included
studies: all trials were comparing TASCT with SASCT as first-line
treatment of symptomatic MM in patients who were either un-
treated or had received conventional treatment, that is non-high-
dose chemotherapy, for a maximum of six months. Features of the
treatment regimen and obvious biases introduced during study
performance (compliance, interaction, course of events in control
group) stopped us from conducting a formal meta-analysis how-
ever (Differences between protocol and review). In order to sum-
marise the results of the individual studies, the number of events
and survival proportions are both listed in Table 7 and recapitu-
lated in a standardised way in the section below. The time course
observed in the Kaplan-Meier (KM) curves (not available for OS
in Bologna96, EFS in MAG95) was added in order to transmit
the maximum amount of information from the individual trials
into the systematic review.
Quality of life was not reported for any included study, which is
deplorable in view of the known adverse effect of ASCT on quality
of life (Campagnaro 2008; Jones 2008). Furthermore, late toxic
effects of ASCT, such as secondary malignancies or infections,
were not specifically reported in any trial (Jantunen 2006; Majhail
2008).
In IFM94 a statistically significant benefit for the tandem arm on
both OS and EFS was observed after a median 75 months of fol-
low-up: Median EFS and OS were prolonged by TASCT from 25
to 30 months and from 48 to 58 months (P = 0.03 and P = 0.01,
respectively). Seven-year OS (21% versus 42%) and EFS (10%
versus 20%) proportions also significantly favoured the tandem-
transplantation group (Table 7). A trend for improved survival
was observed in the long-term follow-up analysis, with a median
11.6 years of follow-up (OS P = 0.08; EFS P = 0.06). No dif-
ference between the second randomisation option (bone marrow
versus peripheral blood stem cells) was observed. Exploratory sub-
group analysis suggested that patients who benefited most from
the TASCT were those who did not achieve at least a very good
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partial response after their first transplantation. It is important to
note that the first ASCT in the TASCT arm was performed with a
lower dose (140 mg/m² melphalan) compared to the only ASCT
in the SASCT arm (140 mg melphalan and TBI) (Table 3) and
may therefore be classified as underdosed from a contemporary
perspective. This is of relevance in view of only 78% of patients in
the TASCT arm actually undergoing the second transplantation.
Treatment-related mortality was observed in 6% of the TASCT
and 4% of the SASCT arm (N = 12 versus N = 8), of which N =
5 (TASCT) and N = 3 were related to the transplantation-related
complication sepsis. Overall, seven different causes of death were
specified (Table 5). Similar two-year survival proportions were ob-
served for patients after relapse in SASCT and TASCT, although
imbalances in salvage treatment limit the interpretability of the
results (see Table 3; Assessment of risk of bias in included studies).
In MAG95, after a median follow-up of 73 months OS appeared
superior in both the TASCTgroup compared to the SASCTgroup
(randomisation option A) and in the group receiving unselected
grafts compared to those receiving selected grafts (randomisation
option B) (P = 0.09 and P = 0.33, respectively) (Table 7). The
prolongation of the median OS from 57 to 75 months in the
TASCT arm might be misleading due to the position of the me-
dian at the right end of the Kaplan-Meier graph with very few
patients at risk. Only a slight prolongation of median EFS was
reported for the TASCT arm (34 versus 31 mo). In the subgroup
of patients who had received unselected grafts, OS was statistically
significantly improved in the TASCT arm compared to patients in
the SASCT arm (P = 0.04), highlighting the potential interaction
of CD34-selection and mortality (Assessment of risk of bias in
included studies; Awedan 2002). Only interim data were available
for MAG95 concerning toxic deaths, based on 85% of the final
study population. For the final analysis, early deaths which in-
cluded myeloma-related deaths (TASCT 7% versus SASCT 12%)
were reported.
The time-course ofmortality as seen in theKaplan-Meier graph for
MAG95 revealed two clusters of events in the control group which
appeared to drive the overall difference between the SASCT and
TASCT arms. The first of the two clusters of events in the control
arm (two to four months post-randomisation) coincided with the
treatment phase of the trial with an almost doubled early mortality
in the SASCT arm (Table 7). In the MAG95 trial, patients in the
TASCT group received the selected graft only at the second ASCT,
while the graft used for the first ASCT was unselected (Table 3;
Assessment of risk of bias in included studies).
Bologna96 did not confirm the significant OS benefit as observed
in the IFM94 trial for TASCT in an ITT analysis (P = 0.9). While
the median OS was extended from 65 (SASCT) to 71 (TASCT)
months, seven-year survival proportions were similar (43% af-
ter TASCT versus 46% after SASCT). No Kaplan-Meier graph
was available for OS. Five-year EFS was significantly better in the
TASCT arm (29% versus 17%) (Table 7). The improvement in
median EFS from 23 to 35 months in the TASCT group was
statistically significant (P = 0.001) with a rather steep decrease in
EFS in the control arm approximately 18months after randomisa-
tion. The duration of relapse-free survival was prolonged from 24
months in the control group to 42 months in the tandem-trans-
plantation arm. Post-relapse survival (PRS), however, favoured the
SASCT arm with a median PRS of 32 months compared to 25
months in the TASCT arm. In view of the low compliance with
the second transplantation in the TASCT group (65%) (Table 3),
the interpretation of results was hampered due to potential null
and selection biases (Assessment of risk of bias in included studies).
Subgroup analysis of patients not reaching complete remission af-
ter induction confirmed the observation of the IFM94 trial sug-
gesting that patients who do not respond well to initial therapy
benefited most from the double intensified protocol. Transplanta-
tion-related mortality (definition see Table 5) was reported as 4%
in the TASCT and 3% in the SASCT arm.
In GMMG-HD2, the final analysis did not demonstrate a signif-
icant prolongation of the median EFS (29 versus 25 mo; no P
value provided) (Table 7). The Kaplan-Meier curves for EFS in
GMMG-HD2 in the ITT population separated only transiently
between 18 months and 38 months (TASCT superior) but the
final proportions of patients surviving event-free were similar (if
more than 10 patients still at risk). Kaplan-Meier curves for OS,
for the ITT population were superimposable. In view of a very low
compliance with the second ASCT (52 % of evaluable patients)
(Table 3), per protocol (PP) analyses were performed in addition
to the ITT analyses (see also Assessment of risk of bias in included
studies). While the per protocol (PP) analysis of EFS was similar
to the ITT analysis, the PP analysis of OS indicated numerically
inferior survival for the TASCT arm over the majority of the fol-
low-up period (Discussion). So-called TRM (definition see Table
5) was reported as 2% during the first and 3% during the second
transplantation compared to 2% in the SASCT group (Table 7).
In DSMM-I, with a follow-up of approximately 48 months (cor-
responding to the entire time axis in the Kaplan-Meier graph) the
Kaplan-Meier curves appeared unstable with multiple crossings
for OS and EFS and a flattening of the curves at the right end
(Assessment of risk of bias in included studies). While OS, EFS
and PFS all appeared superior for the TASCT group, final survival
proportions were favourable for the SASCT arm (Table 7). Ka-
plan-Meier graphs presented later (Einsele 2007), indicated that
PFS was consistently higher for the SASCT arm. No information
was reportedwith respect to the type of analysis (ITT, PP, subgroup
analysis?). So-called TRM (definition see Table 5) was reported as
4% for the TASCT and 3% for the SASCT arm. The definition
of so-called TRM remained unclear. Notably, OS in the TASCT
arm remained at 100% for 400 days (including treatment phase?
) in the TASCT arm (Table 7).
D I S C U S S I O N
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Empirical research should always take into account previous ex-
perience, either to build on it, refute it, or at least to learn from it
(Clarke 2004; Chalmers 2009). Systematic reviews or meta-anal-
ysis are formalised tools to review available evidence on a clearly
defined question. They are also an occasion to systematically and
rigorously assess the quality of the available evidence (Egger 2001).
The findings of a comparison of two treatments, that is the treat-
ment effect, may result from a) improvement of an outcome by the
test treatment, b) an inferior outcome of the control treatment,
c) a chance finding, or even in the setting of a RCT d) be driven
by confounding factors within a small and heterogeneous patient
population (Blair 2004). All four options should be addressed in
the course of an exploratory systematic review. Both patient char-
acteristics and study design (including the treatment plan) should
be scrutinised for their propensity to favour one or more of the
four possibilities. While a systematic review as a retrospective ob-
servational study cannot settle a controversy, the examination may
help to contribute to the design of future studies addressing (an
emerging) one.
Summary of main results
In the set of publicly available RCTs performed between 1994
and 2002 (five of seven completed RCTs), TASCT was accompa-
nied by a statistically significant improvement in OS compared to
SASCT for the first-line treatment of patients with MM in one
study only (IFM94; statistical significance not confirmed in long-
term follow-up). In the other four trials it appeared to have no
effect on survival (Table 7). None of the studies were adequately
powered for the analysis of OS and considerable confounding due
to varying access to salvage treatment is likely. Of note, OS ap-
peared numerically inferior for the per protocol population of the
GMMG-HD2 trial, which may be due to the selection of patients
who proceeded to second transplantation. An observational study
withmatched pair design also reported on numerically inferior OS
(NMSG), as well as a reported case series from a single centre ex-
perience (Koren 2010), highlighting the necessity to further study
the impact of the second transplantation on long-term outcomes.
TASCT improved EFS compared to SASCT in four of the five
trials (not in DSMM-I) (Table 7), but the effect was statistically
significant only in the two trials published as full-text articles (
IFM94; Bologna96). The beneficial effect on EFS appeared to be
transient in GMMG-HD2. The results of DSMM-I appeared to
be too immature to allow firm conclusions.
Treatment- or transplant-related mortality, sometimes indiscrim-
inately summarised as so-called TRM, was higher for the TASCT
arm in four of five studies without reference to statistical signif-
icance (all except MAG95). For MAG95, both the time course
of events in the Kaplan-Meier graph and interim data indicate
that here the SASCT regimen claimed more early and toxic deaths
compared to the TASCT regimen.
Quality of life was not reported in any of the included studies.
Response to treatment had not been assessed for the present review.
In view of the observed heterogeneity of treatment concepts and
the extent of potential bias in the individual studies, we refrained
from performing a formal meta-analysis (Feinstein 1995). Critical
features in the set of included trials concern major differences in
the treatment plans, not only between but also within individual
RCTs. Variable compliance with the planned treatment during
performance of the trials and the potential confounding of OS
data by subsequent treatment may also impact on the observed
treatment effect. Overall, the direction of bias was considered as
unpredictable (Risk of bias in included studies; Quality of the
evidence; Figure 2).
Overall completeness and applicability of
evidence
Publication bias
Two completed or terminated RCTs were identified in clini-
cal trials registries, however they remained unpublished. For the
only American trial (DM00-196), an interim analysis in abstract
form reported on a critical lack of compliance with the second
ASCT, without follow-up data (Wilson 2003). The UK-based
study (N0265041749) reported on similar problems with accrual,
which resulted in early closure of the trial (Mahendra personal
communication). Three of the five included RCTs (DSMM-I;
GMMG-HD2; MAG95) were available as conference presenta-
tions only, emphasising both the necessity to include non-full text
information when systematically evaluating a treatment concept
in oncology and the difficulty of accepting conference presenta-
tions in view of low reporting quality (Ramsey 2008; Tam 2008).
Of note, only the two journal articles report statistically significant
improvements in survival endpoints (IFM94; Bologna96), while
the conference abstracts refer to non-significant results or to diffi-
culty in actually performing the second transplantation (Hopewell
2009). Overall, it appears as if only positive results of TASCT are
published in widely accessible medical journals while the scien-
tific community is not equally informed on disappointing results,
concerning either practicability or clinical outcome.
On the one hand, lack of reporting of clinical outcome data is an
obvious sign of publication bias, a well-known phenomenon in
clinical research (Curt 2008; Ramsey 2008). On the other hand,
the problems with either accrual of patients or low compliance
with the protocol illustrates the strenuous nature of a TASCT
regimen.
Baseline characteristics
Even in RCTs, relevant imbalances at baseline may help to explain
the relative outcome of the study arms (Blair 2004). MM is a very
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heterogeneous disease and the evaluable set of of participants of
some of the trials was only around 100 (compliant) patients per
arm (DSMM-I; GMMG-HD2; Bologna96), which may be insuf-
ficient to balance out chance findings (Moore 1998). In addition,
no information on cytogenetic characteristics was collected in the
included trials. The cytogenetic information is regarded as critical
for extrapolation of results, since cytogenetic analysis belongs to
the basic workup for contemporary patients with MM (Munshi
2011).
Treatment regimen
When reviewing literature, it is important to take into consider-
ation recent improvements in individual steps of the rather com-
plex intervention of autologous stem cell transplantation (Awedan
2002; Attal 2007; Harousseau 2009a). Preparation of patients for
ASCT has changed substantially during the last two decades, in-
cluding induction treatment, mobilisation or handling of stem
cells and a conditioning regimen for ASCT.While induction treat-
ment used to be a combination chemotherapy with vincristine,
doxorubicin and dexamethasone (VAD), or high-dose steroids,
nowadays the so-called ’novel agents’ have replaced the classical
induction regimen (Lane 2005; NCCN 2011). Furthermore, for
contemporary ASCT, only peripheral blood stem cells without
graft manipulation (for example purging of tumour cells) are used
for ASCT in view of better engraftment characteristics when com-
pared to bone marrow (Gratwohl 2007). TBI has been largely
abandoned as a conditioning regimen in view of increased toxicity
(Moreau 2002; Tricot 2009). In addition, the conditioning regi-
men for the second ASCT in the TASCT arm included busulfan,
which has recently been associated with a high treatment-related
morbidity, possibly impacting on further access to salvage treat-
ment (Lahuerta 2010). Today, 200 mg melphalan is considered to
be the standard conditioning regimen (Giralt 2010). It is impor-
tant to note that the regimen used for both TASCT and SASCT
followed the learning curve of the development of the standard
regimens in use today, that is all regimens would be considered
substandard from a contemporary perspective in at least one or
even several components (Table 3).
Overall, treatment regimens were diverse in the included trials,
with notable differences in toxicity between trials but also between
study arms, thereby potentially biasing the overall results (lead-
time bias). The low compliance with the second transplantation
in three trials (IFM94, Bologna96 and GMMG-HD2) (see Table
3) makes the interpretation of treatment effect difficult in view of
unassessable attrition bias, even more so as the TASCT regimen
in IFM94 and MAG95 followed a sort of dose-escalating scheme.
Both MAG95 and DSMM-I applied non-standard SASCT regi-
mens to the control group, which also needs to be considered for
the interpretation of data since treatment effects may stem from
a superior test regimen or from an inferior control arm. Overall,
the possibility of extrapolating the available evidence to treatment
decisions for contemporary patients is questioned.
Quality of the evidence
For interpretation of the effect on OS, the following issues were
regarded as critical in the course of the present systematic review:
confounding by subsequent treatment (all studies), compliance
with the second transplantation (IFM94; Bologna96; GMMG-
HD2), acute toxicity of control treatment (DSMM-I; MAG95),
extent of cross-over (DSMM-I), and time course of mortality (
MAG95). The observed cluster of events in the control armduring
the treatment phase of the only transplantation in the SASCT arm
of MAG95 is indicative of an increased toxicity in the SASCT
arm, that is an inferior outcome for the control arm.
For interpretation of the effects on EFS, the following issues
were regarded as critical: extent of cross-over (DSMM-I), low
compliance with the second transplantation (IFM94; Bologna96;
GMMG-HD2). Furthermore, it remained unclear whether any of
the studies made provisions to address relevant biases introduced
by irregular or asymmetric assessments for events in the course of
the EFS assessments (CHMP/EWP/27994/08 2008). In addition,
events for EFS were defined differently between trials (Table 4)
In the included trials both definitions of the relevant period of
observation and causes of death to be listed as so-called TRM
remained unclear, and were not comparable between trials (Table
5). Another uncertainty concerning the comparability of study-
specific results stemmed from the different level of sophistication
of ascribed causes of death (for example IFM94). In addition, the
definition of the population in which so-called TRM was reported
as a percentage was missing for most trials. This is of relevance
in view of the low compliance with second transplantation, since
there may be large deviance between different populations in the
analysis (for example ITT or ’as treated’).
The short-term risk would need to be counterbalanced by a con-
vincing prolongation of long-term survival accompanied by an
improved quality of life. The per protocol population of GMMG-
HD2, a matched-pair analysis and a single-centre experience
(GMMG-HD2; NMSG; Koren 2010), although all methodically
contestable pinpoint to a potentially inferior survival outcome for
patients actually undergoing second transplantation compared to
a SASCT regimen. More information is required on the long-term
benefit for patients in view of the overall strenuous treatment ap-
proach of TASCT.
Agreements and disagreements with other
studies or reviews
Only one othermeta-analysis on the same topic has beenpublished
(Kumar 2009). In their conclusion, Kumar et al advised against the
routine use of TASCT in view of statistically significantly increased
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treatment-related mortality without significant prolongation of
OS (Kumar 2009).
The discouragement of first-line TASCT triggered substantial crit-
icism among US experts in MM, accompanied by a controver-
sial discussion on the methods and interpretation of data in the
meta-analysis (Giralt 2009;Mehta 2009; Tricot 2009).On the one
hand, the clinicians commenting on the meta-analysis were disap-
pointed that important clinical aspects had not been discussed in
the course of the meta-analysis, for example the impact of salvage
treatment, the use of TBI in the older trials or the different defini-
tions of TRM in the set of included trials. On the other hand, the
authors of the meta-analysis objected to methodically problematic
proposals for analyses or interpretations of available evidence by
the clinicians (Kumar 2009a; Kumar 2009b).
The present systematic review differs from Kumar 2009 in sev-
eral aspects. First, with respect to the set of included trials, Ku-
mar included Sonneveld 2007 which in our view is not assessing
TASCT but rather a non-myeloablative double-intensified proto-
col (Excluded studies). DSMM-I, included in our analysis, was
not mentioned by Kumar et al. While DSMM-I yielded indefinite
results for all outcomes, Sonneveld reported statistically significant
results for EFS (TASCT better) and TRM (TASCT worse).
Second, the focus of our qualitative assessment of included studies
exceeded the prospectively planned elements (such as reporting of
sample size calculations or definitions of endpoints) of trial design
considered by Kumar et al. Here, we integrated both additional
design elements of the trial into the assessment (for example acute
toxicity of treatment regimen) as well as actually observed effects
during trial performance (such as time course of mortality, com-
pliance with treatment) (Other potential sources of bias).
While Kumar presented meta-analytical results, we considered the
observed clinical and methodological heterogeneity as being too
pronounced to gain further insights from a combined analysis.
We agree with Kumar’s conclusion that a short-term risk needs
to be counterbalanced by a long-term benefit in order to justify
routine use of amedical intervention.We also consider it likely that
there is only a marginal, if any, beneficial effect of TASCT on OS.
Thus, we agree in questioning the value of tandemautologous stem
cell transplantation as a first-line treatment in MM. We hestitate
to follow Kumar et al, however, with respect to the informative
value of the increased TRM observed after TASCT. We raise the
question that if an inevitably life-threatening procedure (ASCT)
was performed twice instead of once, would we not even expect
an at least doubled risk of transplantation-related mortality (Jones
2008)? In addition to the diversity of the defintions of TRM used
(Table 5), the low compliance with the second transplantation
(Table 3) may further complicate a definite analysis of treatment-
or transplantation-related mortality.
We also deplore the low precision of reporting on this important
outcome of patients’ safety (Table 5). It remained unclear whether
treatment- or transplant-related mortality was reported when the
ambiguous abbreviation was used (GMMG-HD2; DSMM-I). Fi-
nally, we do not agree with Kumar that TRM in MAG95 might
have been so high that the authors refrained from reporting it. As
described above, we even consider an exceptionally high mortality
in the SASCT arm of MAG95 as plausible in view of the Kaplan-
Meier graph of the final analysis, interim data on toxic death and
the expected toxicity of the treatment regimen based on dose den-
sity (Other potential sources of bias; Effects of interventions).
Overall, we aimed at contributing to improvements of future trial
designs on tandem transplantation rather than settling the conflict-
ing evidence on TASCT, also considering the evolution of treat-
ment approaches of MM in the last decade. We therefore elaborate
in some detail on the difference of the treatment approaches to
TASCT, then and now, and discuss further methodological issues
that prevent clear-cut interpretation of data, especially for con-
temporary patients (Other potential sources of bias; Implications
for practice; Implications for research). We doubt that these po-
tentially confounding issues could be adequately addressed and
recompensed in an individual patient data (IPD) analysis.
We regret to conclude that the set of available RCTs do not yield
sufficient evidence for contemporary treatment decisions.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The present systematic review critically questions the validity of
the included set of trials to provide a basis for contemporary treat-
ment recommendations, especially for patients who have already
achieved a good response after the first transplantation. Treatment
of MM has changed dramatically in the past 15 years and there
are considerable uncertainties and potential sources of bias in this
rather old set of trials. In addition, the quality of reporting of trial
methods and results, especially in those trials available as confer-
ence presentation only, do not allow us to draw firm conclusions.
The uncertainty in the medical community as to whether the
acute toxicity of a second ASCT is counterbalanced by long-term
benefit is also reflected in the design of a number of recent and
ongoing trials, and current treatment guidelines. In view of the
increase in the proportion of complete responses after a second
transplantation in the set of included trials, the option of a sec-
ond transplantation is sometimes limited to patients who have
not responded optimally to the first transplantation (for example
Kortüm 2010). The dependency of a second transplantation on
a suboptimal response to first ASCT was already integrated into
the unpublished DM00-196 trial, and into the current genera-
tion of studies performed by the IFM and GMMG study groups
(for example GMMG-HD5 or Moreau 2011 studies). Also, Cavo
highlights the necessity of evaluating the additional benefit of a
second transplantation in view of the high complete response rates
already obtained with the novel induction regimen (Cavo 2010).
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Implications for research
The observation that, for various unavoidable reasons, compliance
with a second transplantation decreased sharply needs to be taken
into account for future trial designs. This finding is also supported
with data described for 2655 patients in a TASCT program in the
European Bone Marrow Transplantation Registry (EBMTR), for
whom a compliance of only 55.3% was observed with the second
ASCT (Morris 2004). Therefore, sample size calculations for stud-
ies assessing TASCT upfront (that is independent from response
to treatment, such as the ongoing study (NCT01109004)) should
take into account that patients may progress prior to or develop
contraindications against a second ASCT, or simply refuse to un-
dergo a second transplantation. This decrease in compliance can-
not be considered at random thus strategies need to be developed
which aim at addressing the expected selection of patients both fit
enough and willing to continue to second transplantation (see also
Wheatley 2006). Alternatively, patients who successfully under-
went first transplantation (and for whom sufficient stem cells were
collected before) could be randomised between different consol-
idation treatment options. While the latter option bears the risk
of introducing selection bias in the absence of objective criteria to
describe the relevant population, it may ultimately avoid the other
biases described at length above.
In view of the difficulty in ascribing specific causes of death in a
multimorbid patient population, we propose reconsideration of
the definition of the important endpoint of treatment- or trans-
plantation-related mortality in order to optimise its clinical util-
ity. Rather than defining the numerator, that is the type of events
which qualify as treatment-related (a challenging and potentially
subjective process (Keirns 2008)), the reporting of all-cause mor-
tality in a relevant period of time (such as ’from randomisation
until three months after completion of intensive treatment’) is
proposed. Specific causes of deaths, such as fatal infection during
aplasia, could additionally be reported for didactic purposes. Early
mortality reflects either too toxic or ineffective treatment, both
of which are undesirable for symptomatic patients in the need of
treatment.
The publication bias, as determined for the RCTs comparing
TASCT with SASCT, emphasises both the necessity and the diffi-
culties in including non-full text information when systematically
evaluating a treatment concept in oncology (Curt 2008; Ramsey
2008; Tam 2008). Reporting of trials still needs to be improved
in order to allow at least an informed discussion on the potential
direction of bias (Hopewell 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bologna96
Methods Central randomisation before induction treatment
Multicentre (N=32) RCT addressing superiority of TASCT
Participants TASCT N=158, SASCT N=163
age < 60 years
Previously untreated, symptomatic or progressive MM Salmon-Durie stage I-III
(Baseline characteristics Table 2)
Interventions 1x 200 mg/m² melphalan + (140 mg/m² melphalan + 12 mg/m² oral busulfan) vs 1 x
200 mg/m² melphalan SASCT
(Treatment regimen Table 3)
Outcomes OS, EFS, transplantation-related mortality in ITT population
(Definition of endpoints Table 4; Table 5)
Notes Journal publication (peer-review)
Null-bias (only 65% compliance with 2nd ASCT)
Potential confounding by subsequent treatment (superior post-relapse survival for
SASCT arm)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central
Allocation concealment (selection bias) Unclear risk Central
Blinding (performance bias and detection
bias)
All outcomes
High risk Unavoidable in view of obvious difference
in treatment plan
Other bias High risk See Table 6 and Figure 2
DM00-196
Methods Randomised phase II trial, no information on method of randomisation
Single centre study comparing without reporting of basic statistical assumption (superi-
ority/non-inferiority)
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DM00-196 (Continued)
Participants Patients of MM not achieving CR by day 180 after initial ASCT (planned for initial
ASCT N=120; interim analysis on N=31 at d180 post transplantation)
No further information on age or stage
Interventions TASCT (1. ASCT: “high dose melphalan”; 2. ASCT: melphalan/topotecan/cyclophos-
phamide) vs SASCT versus maintenance with thalidomide/dexamethasone
Outcomes PR and CR, relative toxicities
Notes Register information; no clinical outcome data for systematic review reported
Steep decrease of compliance with second ASCT (high refusal rate by patients to proceed
to second transplantation, developing contra-indications, denied coverage by insurance)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk NR
Other bias Unclear risk NR
DSMM-I
Methods Randomisation of patients with at least stable disease after induction and successful stem-
cell mobilisation
Multicentre (N= 46-49) RCT addressing superiority of experimental SASCT regimen
compared to trial; TASCT
Participants TASCT N=98; SASCT N=100
≤60 years;
de novo or max. < 6 cycles of “conventional Ctx”
Salmon-Durie stage II and III
(Baseline characteristics Table 2)
Interventions 2 x 200 mg/m² melphalan TASCT compared to experimental SASCT (chemo-radio
conditioning regimen)
(Treatment plan Table 3)
Outcomes OS, EFS (primary endpoint), so-called TRM
(Definitions of endpoints Table 4; Table 5)
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DSMM-I (Continued)
Notes Conference presentations with some inconsistencies
Safety population differs notably from ITT population (TASCT N=118; SASCT N=
80)
Data likely immature
Total follow-up of only 48-61 months according to Kaplan-Meier graph (reported as
median follow-up)
Potential confounding by cross-over from SASCT to TASCT in 18% of patients and by
subsequent treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding (performance bias and detection
bias)
All outcomes
High risk Unavoidable in view of obvious difference
in treatment plan
Other bias High risk See Table 6 and Figure 2
GMMG-HD2
Methods Randomisation of patients with at least stable disease after induction
Multicentre (N=66) RCT comparing TASCT with SASCT without reporting of aim
(superiority/non-inferiority)
Optional additional randomisation of induction regimen (VID vs VAD)
Participants TASCT N= 180; SASCT N=178 (evaluated patients; actual number of patients depend-
ing unclear and different in different conference presentations (N=358-485)
age 18 - 66 years
previously untreated (or max 6 cycles of conventional chemotherapy) patients with MM
Salmon-Durie stage II and III
(Baseline characteristics Table 2)
Interventions 2 x 200 mg/m² melphalan TASCT vs 1 x 200 mg/m² melphalan SASCT (Treatment
plan Table 3)
Outcomes OS, EFS (primary endpoint), so-called TRM (ITT and PP analyses)
(Definitions of endpoints Table 4; Table 5)
Notes Conference presentation with some inconsistencies
Unclear, how the two randomisations were analysed (separately?, interaction test?)
Very low compliance (52% of evaluable population) with 2nd ASCT (null bias for OS,
EFS);
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GMMG-HD2 (Continued)
Potential confounding by salvage treatment (OS)
Numerically inferior OS for TASCT group in PP analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding (performance bias and detection
bias)
All outcomes
High risk Unavoidable in view of obvious difference
in treatment plan
Other bias High risk See Table 6 and Figure 2
IFM94
Methods Central randomisation at diagnosis
Multicentre (N=45) RCT assessing superiority of TASCT
2x2 factorial design: additional randomisation between bone marrow and peripheral
blood stem cells
Participants TASCT N=200, SASCT N=199; (long-term follow-up: TASCT N=203; SASCT N=
199)
age < 60 years
Previously untreated patients with MM Salmon-Durie stage I (with bone lesion), II-III
(Baseline characteristics Table 2)
Interventions ”Dose-escalating“TASCT regimen compared to SASCT (conditioningmelphalan +TBI
8 Gy) - both either with bone marrow or peripheral blood stem cells
(Treatment regimen Table 3)
Outcomes OS, EFS, treatment- and transplantation-related mortality in ITT population
(Definition of endpoints Table 4; Table 5)
Notes Journal publication (peer review)
Long-term follow-up data for OS and EFS available
No clinically relevant interaction of two randomisations
Dose-escalating” TASCT regimen not comparable to current treatment approaches
(dose of first ASCT lower than only ASCT in SASCT arm)
Low compliance (75%) with second ASCT in TASCT arm
Potential confounding subsequent salvage treatment (inferior post-relapse survival in
TASCT group)
Risk of bias
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IFM94 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central
Allocation concealment (selection bias) Low risk Central
Blinding (performance bias and detection
bias)
All outcomes
High risk Unavoidable in view of obvious difference
in treatment plan
Other bias High risk See Table 6 and Figure 2
MAG95
Methods Randomisation before induction treatment
Multicentre (number not reported) RCT without reporting of basic statistic assumption
(superiority/non-inferiority)
2x2 factorial randomisation (unselected vs CD34 selected PBSC)
Participants TASCT N=114, SASCT N=113
age <56 years
Previously untreated patients with MM Salmon-Durie stage II and III
Interventions “Dose-escalating” TASCT vs SASCT (combination chemotherapy + 12 Gy TBI); both
with- and without selection of CD34-positive cells
Outcomes OS, median EFS; early death (toxic deaths for interim analysis, only)
Notes Conference presentations
Clinically relevant interaction of two randomisations (inferior outcome after selection
of CD34+)
Non-standard conditioning regimenwith high dose TBI (12Gy)with asymmetric course
of toxicity between two arms (later onset of high toxicity in TASCT arm)
Potential confounding by subsequent salvage treatment (OS)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding (performance bias and detection
bias)
All outcomes
High risk Unavoidable in view of obvious difference
in treatment plan
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MAG95 (Continued)
Other bias High risk See Table 6 and Figure 2
N0265041749
Methods Randomised trial (no further information) following stem cell collection
Single centre RCT assessing superiority of TASCT
Participants No information on planned or recruited number of patients
age < 65 years
Newly diagnosed (up to 3 months after diagnosis) patients with chemosensitive MM
Salmon-Durie stage II-III
Interventions Double vs single high-dose melphalan
(Treatment regimen Table 3)
Outcomes OS, quality of life
Notes Register information (no clinical outcomes reported)
According to principal investigator study failed to recruit a “sufficient number of patients”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk NR
Other bias Unclear risk NR
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
EBMTR Insufficient information on baseline characteristics (less than 5 factors without substantial missing data)
Insufficient information on treatment plan, already apparent imbalances between use of TBI in the “planned” or
“unplanned” group
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(Continued)
Kim 2009 No separate information on patients receiving either one or two transplants
Koren 2010 No separate information on patients receiving either one or two transplants
Lahuerta 2003 No separate information on patients receiving either one or two transplants
NMSG Insufficient information on baseline characteristics (less than 5 factors)
Insufficient information on treatment plan.
Sonneveld 2007 Non-myeloablative dosing regimen of melphalan (2 x 70 mg/m²)
Total therapy No RCT.
No contemporary control group.
Of note: integration of novel agents in TT generation >1 is regarded as a critically different treatment approach
compared to the set of included RCTs
Characteristics of ongoing studies [ordered by study ID]
NCT01109004
Trial name or title A trial of single autologous transplantation with or without consolidation therapy versus tandem autologous
transplantation with lenalidomide maintenance for patients with MM (BMT CTN 0702)
Methods Randomised, multicenter (N=52), open-label, three-arm trial
Participants Up to 750 patients with symptomatic MM who have received at least two cycles of any regimen as initial
systemic therapy and are within 2 - 12 months of the first dose of initial therapy and with an adequate
autologous graft
< 70 years
Interventions TASCTplusmaintenance therapy versus the strategy of SASCTplus consolidation therapywith lenalidomide,
bortezomib anddexamethasone (RVD) followedbymaintenance therapy or SASCTplusmaintenance therapy
as part of upfront treatment of MM. Lenalidomide will be used as maintenance therapy for three years in all
arms
Outcomes Primary 3 year PFS, 3 year OS, Quality of life, treatment-related mortality
Starting date May 2010 - May 2016 (estimated final data collection date for primary outcome measure)
Contact information Mary Horowitz, MD, MS http://clinicaltrials.gov/ct2/show/NCT01109004?term=NCT01109004&lup s=
01%2F30%2F2011&lup d=30
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Searching for trials: Inclusion and exclusion criteria for eligibility
General aspects
Accepted study designs Studies with contemporary control groups (RCT or observational)
Accepted date of publication 1995-2011
Accepted publication type RCTs: full text, abstract, conference presentation
Observational studies: full-text only
Inclusion criteria
I1 Patients with previously untreated symptomatic MM (excluding the prognostically very different
plasma cell leukaemia (International MyelomaWorkshop 2003)) comprising at least 85% of the study
population
I2 Intervention group: tandem autologous stem cell transplantation
I3 Control group: single autologous stem cell transplantation
I4 At least one of patient-relevant outcomes reported (OS, EFS, transplantation- or treatment-related
mortality)
I5 Observational studies: comparability of study groups with detailed information for at least 5 relevant
prognostic criteria per arm
Exclusion criteria
E1 Other research questions (e.g. basic research, other therapeutic approaches, other diseases, prognostic
studies) or publication type (e.g. narrative review, editorial, letter without original data)
E2 Duplicate publication without additional information1
E3 Report without quantifiable/assignable outcome measures of first-line treatment in patients with MM
E4 No acceptable study design (or, in addition, publication type for observational studies)
E5 Low number of evaluable patients per arm (< 25 patients per arm for RCTs, < 50 for observational
studies)2
E6 Other Language of publication than English, French or German
1 For cumulative reports such as registry data, only the last publication was included. Abstract presentations of included RCTs published
in full-text were only included if they contained additional data (e.g. long-term follow-up).
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2 In view of the lower relevance of non-randomised studies for assessment of intervention effects, larger studies were required for
inclusion.
Table 2. Baseline characteristics of patients
Base-
line charac-
teristics
N Age
[y]
β2 micro-
globulin
[mg/l]
Sex
[% male]
Durie
Salmon
stage
n (%)
Status at
Rdx
Prognostic
factors re-
ported (n)
Note
IFM94
TASCT
200;
[203* in
LTFU]
52 ± 6
[mean]
5±9 55 I: 14 (7)
II: 31 (16)
III: 155 (78)
Untreated Age, Alb,
B2M,
BMcyt., Ca,
Crea, CRP,
DS,
Hb, LDH,
M protein
Sex (12)
“No sig-
nificant dif-
ferences be-
tween
groups”SASCT
IFM94
199
[198*
in LTFU for
EFS]
52 ± 6
[mean]
5±6 56 I: 17
II: 23
III:159
MAG95
TASCT
114 50
[22-56]
(overall)
2.8 [0.9-65]
(overall)
NR I: NR
II: - (12)
III: - (85)
(overall)
Newly
diagnosed
Age, B2M,
DS, M pro-
tein
(4)
“No sig-
nificant dif-
ferences be-
tween
groups”,
not reported
per treat-
ment arm
MAG95
SASCT
113
Bologna96
TASCT
158 53± 6 4.6±7.8 60 I: 31 (20)
II: 29 (18)
III: 98 (62)
Previously
untreated
Age; B2M;
BM cyt.;
CRP; Crea.;
DS; Hb; Pt;
M protein;
Sex (10)
“No statisti-
cally signifi-
cant dif-
ferences be-
tween
groups”
Bologna96
SASCT
163 52± 6 4.2±5.2 61 I: 32 (20)
II: 23 (14)
III: 108 (66)
GMMG-
HD2
TASCT
180* 56 (med.) 2.8 [med.] NR I: (excl.)
II:
III: (63% in
interim
analysis)
At least SD
after induc-
tion
Age, Alb,
B2M, CRP,
Hb,
(5)
Reported
factors simi-
lar after vi-
sual inspec-
tion;
to-
tal number
of included
patients
unclear (N=
358-485);
GMMG-
HD2
SASCT
178* 55 (med.) 2.5 [med.] NR I: (excl.)
II:
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Table 2. Baseline characteristics of patients (Continued)
III: (70% in
interim
analysis)
DSMM-I
TASCT
(immature)
98 54
(30-60)
[>3.5 g/dl]
31.6%
63 I: (excl.)
II: 28%
III: 72%
At least SD
after induc-
tion and suf-
ficient num-
ber
of stem cells
collected
Age,
B2M, Crea,
DS, LDH,
M protein,
bone,
sex
(8)
“No statisti-
cally signifi-
cant dif-
ferences be-
tween
groups”
DSMM-I
SASCT
(immature)
100 54
(34-61)
[>3.5 g/dl]
29%
63 I: (excl.)
II: 38%
III: 62 %
roundedfigures; Alb: serumalbumin; B2M:β2microglobulin; BMcyt: bonemarrow cytosis; Ca: serumcalcium;Crea: serumcreatinine;
CRP: C-reactive protein; DS: Durie-Salmon stage; Hb: haemoglobin; LDH: serum lactate dehydrogenase, LTFU: long-term follow-
up; Pt: platelets; Rdx: randomisation
~ median OS read of KM curves; * evaluated patients
Table 3. Treatment regimen in included studies
Study Stem cell
mobilisa-
tion/
source
(type; mini-
mal
number per
transplant
Induction Condition-
ing ASCT
Compli-
ance ASCT
Mainte-
nance
[Compli-
ance]
Salvage Cross-over
(SASCT to
TASCT)
Notes
IFM94
TASCT
G-CSF
for PBSC or
BM harvest
after induc-
tion;
(PBSC or
BM; 2*106
CD34+/kg)
3-4 x VAD 1. Mel 140
2.Mel 140+
8 Gy TBI
1. 88%
2. 78%
Interferon
α;
[49%]
59%,
e.g.
21% Thal.,
17% SCT
/ 2nd rdx
BM/PBSC
no clinically
relevant in-
teraction;
differ-
ent dose in-
tensity up to
first ASCT;IFM94
SASCT
as TASCT as TASCT Mel 140 +
8 Gy TBI
85% Interferon
α; steroids;
[57%]
68% e.g.
12% Thal.,
17% SCT
NR
MAG95
TASCT
CYP, G-
CSF;
PBSC
(PBSC;NR)
HD steroids
and ?
1. Mel 140
2. Mel 140
+VP16
+12 Gy TBI
1st: 100%
2nd: 92%
NR or none NR / Stem cell
col-
lection after
high-dose
steroids;
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Table 3. Treatment regimen in included studies (Continued)
clinically
relevant in-
teraction be-
tween
purging and
ASCT arm;
no-
tably differ-
ent dose in-
tensity and
dose density
up to and in-
cluding first
ASCT
MAG95
SASCT
as TASCT HD steroids
and 3 x
“VAD-like”
BCNU
+VP16,
+Mel 140
+CYP
+ 12 Gy TBI
94% NR NR NR
Bologna96
TASCT
CYP
G-CSF
(PBSC
2*106
CD34+/kg)
4 x VAD 1. Mel 200
2. Mel 120 +
oral BU
(4 mg/kg d-
5 to d-3)
1st: 90%
2nd: 65%
[e.
g. refused by
patient: 7%]
Interferon
α;
[55%]
10% SCT
55% novel
agents
/ Same dose
intensity
and density
up to and in-
cluding first
ASCT;
Bologna96
SASCT
as TASCT as TASCT Mel 200 85% Interferon
α;
[77%]
33% SCT;
50% novel
agents
NR
GMMG-
HD2
TASCT
HD CYP/
IFO
G-CSF
(PBSC; NR;
purging op-
tional)
VID
or VAD (up
to 6 cycles;
until CR or
plateau)
1. Mel 200
2. Mel 200
1st: 93%*
2nd: 52%
[re-
fused by pa-
tient: 28%)
Interferon
α;
[NR]
> 20% sal-
vage SCT;
>40%novel
agents )
/ No in-
teraction re-
ported
for optional
randomisa-
tion VID vs
VAD (VAD
less toxic)
and ASCT;
same dose
intensity
and density
up to and in-
cluding first
ASCT
GMMG-
HD2
SASCT
as TASCT as TASCT Mel 200 88% Interferon
α;
[NR]
(no
info per arm
reported
NR
DSMM-I
TASCT
IEV + G-
CSF
(PBSC
2*106
CD34+/kg)
4 x ID 1. Mel 200
2. Mel 200
1st: NR
2nd: NR
Interferon
α;
[NR]
NR / Dif-
ferent dose
intensity up
to and in-
cluding first
ASCT
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Table 3. Treatment regimen in included studies (Continued)
DSMM-I
SASCT
as TASCT as TASCT BU CYP
+ 9 Gy TMI
72% Interferon
α;
[NR]
NR 18% (time
point not re-
ported)
Current
standard
and report-
ing recom-
mendations
HD CYP +
G-CSF;
unselected
graft
novel agent
plus dexam-
ethasone
Mel 200;
no TBI
Consider to
in-
crease num-
ber of drop-
out for sam-
ple size cal-
culation
Report com-
pliance per
arm
Report
number of
patients and
outcome per
arm
Report
number of
patients and
time point/
status
at cross-over
per arm;
BM: bonemarrow; BCNU: carmustine; BU: busulfan; CD34: cluster of differentiation (stem cell marker); CR: complete response; CYP:
cyclophosphamide; G-CSF: granulocyte-colony stimulating factor; Gy: Gray; HD: high-dose; IFO: ifosfamide; IEV: Ifosfamide,
epirubicin, etoposide; ID: idarubicin, dexamethasone; Mel: Melphalan; NR: not reported; PBSC: peripheral blood stem cells; rdx:
randomisation; SCT: stem cell transplant; TBI: total body irradiation; TMI: total marrow irradiation; VAD: vincristine, adriamycin,
dexamethasone; VID: vincristine, idarubicine, dexamethasone
VP16 etoposide
* of evaluated patients
Table 4. Definition of survival outcomes
Study d0 OS EFS Response
criteria
Progression Relapse Follow up
(med.)
Note
IFM94 Diagnosis Death Progression
relapse
death
IFM (pre-
EBMT)
methods
without im-
munofixa-
tion, i.e. over-
estimation of
CR
25% increase
in the para-
protein level
after two cy-
cles of the ini-
tial chemo-
therapy;
After CR
reappearance
ofM-protein,
recurrence of
bone marrow
infiltration,
or both
after response
50% increase
above
the plateau of
M-protein in
two sam-
ples obtained
4 weeks apart
75 mo /
11.6 y
Including pe-
riod of induc-
tion and mo-
bilisation,
lower sensi-
tivity with re-
spect to
detecting re-
lapse without
immunofixa-
tion
MAG95 After HD
steroids be-
fore mobili-
sation
NR NR NR NR NR 73 mo Including pe-
riod of induc-
tion and mo-
bilisation
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Table 4. Definition of survival outcomes (Continued)
Bologna96 Start of
treatment
Death Progression
relapse
death
EBMT+
nCR
(=CR
with positive
immunofixa-
tion)
Respon-
ders: > 25%
increase in M
protein from
nadir and/or
appearance of
new bone
lytic lesions
non-respon-
ders: > 25%
increase in M
protein from
baseline and/
or appear-
ance of new
bone lytic le-
sions
After CR/
nCR
reappearance
of M pro-
tein on im-
munofix-
ation or rou-
tine electro-
phoresis, re-
spec-
tively, and/or
appearance of
new bone
lytic lesions
70 mo (sur-
vivors only)
Including pe-
riod of induc-
tion and mo-
bilisation
GMMG-
HD2
Unclear NR NR NR NR NR Unclear
2003: 36
months
2005: 24
months
2007: NR
Refer-
ence point for
time-to event
and follow-
up unclear;
likely exclud-
ing induction
but including
mobilisation
in selected
patients
DSMM-I Unclear NR NR NR NR NR 48 mo total?? Refer-
ence point for
time-to event
and follow-
up unclear; so
called TRM
of
4% reported
for TASCT
arm but OS
at 100% for
500 days of
FU
CR: complete response; EBMT: European Bone Marrow Transplantation; FU: follow-up; IFM: Intergroupe francophone du myelome;
med: median; mo: months; nCR: near complete response
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Table 5. Defition of treatment- or transplant-related mortality
Study Definition used How reported
in which popula-
tion
Start
point
Period Other causes of death reported sepa-
rately
IFM94 Treatment-related
mortality:
“toxic effects of
transplantation (sep-
sis)”
“toxic effects to VAD
(sepsis)”
number of deaths; %
per arm; ITT
Unclear NR “Death due to myeloma”;
“cardiovascular or thrombo-
embolic disease”
“another cancer”
“unknown cause”
“suicide”
MAG95[1] Interim analysis:
“Toxic death”1
(performed with
85% of final popula-
tion)
Final analysis “Early
death”
“death within
9 months post ran-
domisation includ-
ing toxic death and
fatal progressive dis-
ease” 2
% per arm; popula-
tion NR
(for both definitions)
Rdx 9 months NR
Bologna96 “Transplan-
tation-related mor-
tality included any
death within 90 days
and attributable to
high-dose therapy”
% per arm;
population NR
SCT 90 days N of deaths as reason for non-compliance
(no cause of death reported)
GMMG-HD2 So-called
TRM (treatment or
transplantation?)
reported without the
clarification of popu-
lation
% per transplanta-
tion per arm; popula-
tion NR3
NR NR NR
DSMM-I So-called
TRM (treatment or
transplantation?)
% per arm; popula-
tion NR
NR NR* NR
1 toxic death lower in TASCT compared to SASCT arm (7% versus 9%)
2 notable difference in dose intensity between TASCT and SASCT resulting in 7% versus 12% early mortality.
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3 only 56% compliance with second ASCT
* plateau of 100% in Kaplan-Meier curve from d1-d400 in TASCT arm despite so-called TRM of 4%; reported safety population for
SASCT N=80; TASCT N=118 since 20 patients crossed over from SASCT to TASCT arm
Table 6. Quality criteria for the assessment of bias
Quality criteria positive negative unclear Consequence of nega-
tive classification
RCT
Central randomisation Performed with ade-
quate methods described
Inadequate methods de-
scribed
Not Reported (NR) Confounding
Concealment of alloca-
tion
Performed with ade-
quate methods described
Inadequate methods de-
scribed
NR Confounding
Statistical power Powered for survival Powered for response NR Underpowered for sur-
vival
Observational studies
Selection of patients Based on transparent cri-
teria; plausible matching
criteria
Indicative of strong se-
lection bias; resulting in
incomparable groups
NR Confounding
Study size Justified Fewer patients than
planned
NR Underpowered for OS
RCT and observational study
Confounding at baseline Reporting of at least 5
key prognostic factors
per arm allowing assess-
ment of similarity of
groups
Relevant difference in
key prognostic factors
obviously present clini-
cally but not addressed
</= 5 factors reported or
no information per arm
Confounding
Comparability of treat-
ment
Treatment identical up
to and including first
ASCT
Notable difference with
onset and duration of
toxic treatment
Unclear Lead-time bias/
confounding
Subsequent treatment Information avail-
able with type and out-
come per arm
No information avail-
able
NR or no info per arm Confounding
ITT analysis Yes, including definition
reported
No Analysis or definition
NR
Selection and attrition
bias with loss of power1
Compliance with 2nd
TASCT
High (> 85%) Low (<70%) 70-85%
or NR
Attrition bias1 or loss of
power2
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Table 6. Quality criteria for the assessment of bias (Continued)
Completeness of follow-
up
<15 % loss to follow-up;
censoring rules defined
Incomplete follow-up (>
15%) with unknown
consequence for analysis
Loss to follow-up or cen-
soring rules NR
Attrition bias1 or loss of
power2
Cross-over Reported and < 15% Reported and > 15% NR Null bias
Definition of endpoints Comprehensive report-
ing of accepted/ estab-
lished endpoint defini-
tions
Use of biased endpoint
(e.g. different period of
observation for study
arms)
Incomplete reporting* Lack of scientific validity
Standardisation of diag-
nostic procedures or cen-
tral review
Mentioning of standard-
isation efforts, use of ac-
cepted staging systems
Reporting of centre ef-
fects or major changes
in diagnostic criteria over
the course of the study
NR Information bias (if sys-
tematically different be-
tween arms)
Data maturity (Tricot
2009)
> 4 years follow-up (FU) Less than 4 years FU NR Insufficient follow-up
Publication
type&
Peer-reviewed full-text Conference
presentations
Not Applicable (NA) Error-prone
due to less proof-reading
(at the least)
NR not reported
1 if informative censoring
2 if at random
* of endpoint definitions with major impact on denominator (e.g. so-called TRM)
Table 7. Effect of TASCT compared to SASCT on OS, EFS and “TRM”
Follow-
up
months
(mo)
Kaplan-
Meier
curve
Median OS Kaplan-
Meier
curve
Median EFS Treatment- or Trans-
plant-related mortal-
ity
Notes
Study OS TASCT SASCT EFS TASCT SASCT TASCT SASCT
IFM94 75 mo
(median)
TASCT
superior;
sep-
aration of
curves af-
ter ca. 26
mo;
58 mo* 48 mo*
P=0.01
TASCT
superior;
sep-
aration of
curves af-
ter ca. 18
mo;
30 mo* 25 mo*
P=0.03
Treat-
ment-
related
deaths
(includ-
ing in-
duction)
N= 12
(6%)
Treat-
ment-
related
deaths
(includ-
ing in-
duction)
N= 8
(4%)
Five addi-
tional
causes of
death
listed;
Long
term fol-
low-
up (11.6
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Table 7. Effect of TASCT compared to SASCT on OS, EFS and “TRM” (Continued)
Trans-
planta-
tion-
related
deaths
(sepsis)
N=5
Trans-
planta-
tion-
related
deaths
(sepsis)
N=3
years)
OS P=0.
08
EFS P=0.
06
MAG95 73 mo
(median)
SASCT
inferior;
(overall
transient)
sep-
aration of
curves af-
ter cluster
of events
in control
arm after
2-
4 and 35
months;
75 mo 57 mo No KM-
curve
34 mo 31 mo Toxic
death (in-
terim
data§):
7%
“Early
mor-
tality” N=
8 (7%)
Toxic
death (in-
terim
data§):
9%
“Early
mor-
tality” N=
13 (12%)
;
Final OS
survival
propor-
tions sim-
ilar
Bologna96
70
mo (me-
dian for
survivors)
no KM-
curve
(inconsis-
tent me-
dian OS
and
7 year OS
(TASCT
43 vs
SASCT
46%) in-
dicate
crossing
curves)
71 mo 65 mo TASCT
superior;
sep-
aration of
curves af-
ter 18
mo;
5 y EFS:
29% vs
17%
35 mo* 23 mo*
P=0.001
Trans-
planta-
tion-
related
deaths
Table 5
4%
Trans-
planta-
tion-
related
deaths
Table 5
3%
Compli-
ance with
second
ASCT:
65%
GMMG-
HD2
Unclear
2003:
36 mo
2005:
24 mo
2007 (fi-
nal): NR
ITT: su-
perim-
posable
curves
(multi-
ple cross-
ings);
PP:
SASCT
slightly
superior
ca. 77 mo ca. 72 mo ITT:
TASCT
tran-
siently su-
perior;
crossing
of curves
at 38 mo;
PP: simi-
lar to ITT
ca. 29 mo ca. 25 mo So-called
TRM
Table 5
1st 2%
2nd 3%
(popu-
lation un-
clear)
So-called
TRM
Table 5
2%
(popu-
lation un-
clear)
Compli-
ance with
second
ASCT:
52% of
evaluable
patients
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Table 7. Effect of TASCT compared to SASCT on OS, EFS and “TRM” (Continued)
DSMM-I ca. 48
months
(reported
as median
follow-
up;
according
to KM:
total fol-
low-up)
TASCT
initially
superior;
crossing
of KM
curves at
36 mo;
4 yr OS
72% in
both arms
Not
reached
Not
reached
TASCT
initially
superior;
crossing
of KM
curves at
22 mo
36,4 mo ca. 43.4
mo
So-called
TRM
(exclud-
ing in-
duction)
Table 5
4%
(popula-
tion?);
(OS at
100% for
400 d ac-
cording
to KM-
curve)
So-called
TRM
(exclud-
ing in-
duction)
Table 5
3%
(popula-
tion?)
high pro-
portion
of cross-
over;
* statistically significant difference; ca. = read from Kaplan-Meier plots
§ interim data with 85% of enrolled patients
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
#7 Search myelom*[Text Word]#8 Search kahler*[Text Word]
#9 Search plasmacytom*[Text Word]
#10 Search plasmocytom*[Text Word]
#12 Search “stem cell transplantation”[MeSH Major Topic]
#13 Search “transplantation, autologous”[MeSH Major Topic]
#14 Search “transplantation, homologous”[MeSH Major Topic]
#16 Search transplant*[Text Word]
#17 Search graft*[Text Word]
#19 Search autolog*[Text Word]
#23 Search autograft*[Text Word]
#24 Search auto-graft*[Text Word]
#25 Search auto-transplant*[Text Word]
#26 Search autotransplant*[Text Word]
#27 Search asct*[Text Word]
#28 Search abmt*[Text Word]
#39 Search “multiple myeloma”[MeSH Major Topic]
#40 Search #7 or #8 or #9 or #10 or #39
#50 Search (#12 or #16 OR #17) AND #19
#52 Search #13 OR #14 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #50
#53 Search #40 and #52
#55 Search (Therapy/Broad[filter] OR EBMT[All Fields] OR IBMTR[All Fields] OR
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(registry[tw] OR register[tw]) OR “center experience”[tw] OR “centre experience” )
AND (“humans”[MeSH Terms] AND (English[lang] OR French[lang] OR
German[lang]) AND (“1995”[PDAT] : “2010”[PDAT]))
#56 Search #53 and #55
Appendix 2. CENTRAL search strategy
1 MeSH descriptor MULTIPLE MYELOMA explode all trees
2 (myelom* or myeloom* or mielom*).tw,kf,ot.
3 myelomatos*.tw,kf,ot.
4 (kahler or kahler’s).tw,kf,ot.
5 (plasm*cytom* or plasmozytom*).tw,kf,ot.
6 #1 or #2 or #3 or #4 or #5
7 MeSH descriptor STEM CELL TRANSPLANTATION
explode all trees
8 MeSH descriptor TRANSPLANTATION, AUTOLOGOUS
explode all trees
9 MeSH descriptor TRANSPLANTATION, HOMOLOGOUS
explode all trees
10 #7 or #8 or #9
11 (transplant* or graft*).tw,kf,ot.
12 autolog*.tw,kf,ot.
13 #11 and #12
14 (autograft* or auto-graft*).tw,sh,ot.
15 (homograft* or homo-graft*).tw,sh,ot.
16 (autotransplant* or auto-transplant*).tw,sh,ot.
17 ((tandem* or double*) near/3 transplant*).tw,kf,ot.
18 (asct or abmt).tw,kf,ot.
19 #14 or #15 or #16 or #17 or #18
20 #10 or #13 or #19
21 #6 and #20
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 10, 2012
Date Event Description
26 May 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
NF: updating protocol (based on earlier version), searching, eligibility screening, data extraction and quality assessment, content input,
interpretation of findings
AG: drafting of first version of the protocol, searching, eligibility screening
PB: interpretation of findings and providing a clinical perspective
JB: methodological expert
AE: providing a clinical perspective
RS: searching, eligibility screening, data checking and quality assessment, interpretation of findings, providing a clinical perspective
D E C L A R A T I O N S O F I N T E R E S T
No interests to declare.
The views and opinions expressed in the systematic review are those of the individual authors and should not be attributed to the
institutions where they are employed.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• New Source of support, Not specified.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
While performing the review, we had to restrict our search to publications in English, French and German and had to exclude the
database EMBASE due to budgetary restrictions.
Initially, it was planned to perform a statistical meta-analysis for the included studies. In view of notable clinical heterogeneity and
several methodological issues, the presented results are limited to a narrative systematic review. Furthermore, response and time-to-
progression were not analysed. In addition to newly diagnosed patients, studies with previously treated patients were acceptable as long
as the treatment was conventional and of limited duration (up to six months). Instead of limiting our systematic search to RCTs as
planned in the protocol, we also searched for observational studies with contemporary control groups.
The outcome transplantation-related mortality was only vaguely defined in the majority of trials. Instead of including only trials
reporting transplantation mortality (as initially planned), we extracted results where all kind of definitions for early mortality were used.
Fewer authors contributed to the finalisation of the review compared to the protocol.
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